- Home
- FMC vs ACAD Comparison
FMC vs ACAD Comparison
Compare FMC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- ACAD
- Stock Information
- Founded
- FMC 1910
- ACAD 1993
- Country
- FMC United States
- ACAD United States
- Employees
- FMC N/A
- ACAD 654
- Industry
- FMC Major Chemicals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- FMC Industrials
- ACAD Health Care
- Exchange
- FMC Nasdaq
- ACAD Nasdaq
- Market Cap
- FMC 4.6B
- ACAD 4.3B
- IPO Year
- FMC N/A
- ACAD 2004
- Fundamental
- Price
- FMC $37.21
- ACAD $25.24
- Analyst Decision
- FMC Buy
- ACAD Buy
- Analyst Count
- FMC 12
- ACAD 20
- Target Price
- FMC $50.58
- ACAD $28.63
- AVG Volume (30 Days)
- FMC 1.6M
- ACAD 2.0M
- Earning Date
- FMC 10-28-2025
- ACAD 08-06-2025
- Dividend Yield
- FMC 6.25%
- ACAD N/A
- EPS Growth
- FMC N/A
- ACAD 615.00
- EPS
- FMC 0.80
- ACAD 1.33
- Revenue
- FMC $4,131,600,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- FMC $0.26
- ACAD $14.01
- Revenue Next Year
- FMC $4.72
- ACAD $11.72
- P/E Ratio
- FMC $46.65
- ACAD $19.23
- Revenue Growth
- FMC 1.16
- ACAD 14.41
- 52 Week Low
- FMC $32.83
- ACAD $13.40
- 52 Week High
- FMC $67.75
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- FMC 40.11
- ACAD 54.66
- Support Level
- FMC $36.26
- ACAD $25.14
- Resistance Level
- FMC $39.99
- ACAD $26.50
- Average True Range (ATR)
- FMC 1.03
- ACAD 0.62
- MACD
- FMC -0.05
- ACAD -0.11
- Stochastic Oscillator
- FMC 22.49
- ACAD 38.76
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.